Market Overview

MacroGenics Enters Collaboration, License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies, MacroGenics to Receive $50M Upfront License Fee, $75M Equity Investment by JNJ

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS

Posted-In: News Financing Contracts

 

Related Articles (JNJ + MGNX)